Preliminary Evaluation of a Recombinant Rift Valley Fever Virus Glycoprotein Subunit Vaccine Providing Full Protection against Heterologous Virulent Challenge in Cattle
Vaccines
Data
2021Autor
Wilson, W.C.
Faburay, B.
Trujillo, J.D.
Ragan, I.
Sunwoo, S.Y.
Morozov, I.
Shivanna, V.
Balogh, A.
Urbaniak, K.
McVey, D.S.
Bold, D.
Gaudreault, N.N.
Schirtzinger, E.E.
Ma, W.
Richt, J.A.
Metadane
Pokaż pełny rekordStreszczenie
Rift Valley fever virus (RVFV) is a mosquito-borne zoonotic pathogen that causes periodic
outbreaks of abortion in ruminant species and hemorrhagic disease in humans in sub-Saharan
Africa. These outbreaks have a significant impact on veterinary and public health. Its introduction
to the Arabian Peninsula in 2003 raised concerns of further spread of this transboundary pathogen
to non-endemic areas. These concerns are supported by the presence of competent vectors in
many non-endemic countries. There is no licensed RVF vaccine available for humans and only
a conditionally licensed veterinary vaccine available in the United States. Currently employed
modified live attenuated virus vaccines in endemic countries lack the ability for differentiating
infected from vaccinated animals (DIVA). Previously, the efficacy of a recombinant subunit vaccine
based on the RVFV Gn and Gc glycoproteins, derived from the 1977 human RVFV isolate ZH548,
was demonstrated in sheep. In the current study, cattle were vaccinated subcutaneously with the
Gn only, or Gn and Gc combined, with either one or two doses of the vaccine and then subjected
to heterologous virus challenge with the virulent Kenya-128B-15 RVFV strain, isolated from Aedes
mosquitoes in 2006. The elicited immune responses by some vaccine formulations (one or two
vaccinations) conferred complete protection from RVF within 35 days after the first vaccination.
Vaccines given 35 days prior to RVFV challenge prevented viremia, fever and RVFV-associated
histopathological lesions. This study indicates that a recombinant RVFV glycoprotein-based subunit
vaccine platform is able to prevent and control RVFV infections in target animals.
Zbiory
- Publikacje [579]